Leukemia/MDS Clinical Trials

Showing 31-38 of 38 items
31.
  • A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
  • This is a Phase 1, open-label, multicenter study evaluating the safety and pharmacokinetics profile of ABT-199 under a once daily dosing schedule in approximately 72 subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin's Lymphoma (NHL). Two arms will be implemented for dose escalation: Arm A, CLL/small lymphocytic lymphoma (SLL) subjects, and Arm B, NHL subjects. The dose escalation phase for each arm will include approximately 24 subjects, with the objective of defining dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). Once the MTD is declared for an arm, approximately 12 additional subjects will be enrolled into the arm in an expanded safety cohort. In addition, subjects in the Arm B (NHL) dose escalation of the study will be evaluated for the food effect of ABT-199.
  • Diagnoses: Leukemia/MDS, Non-Hodgkin's Lymphoma
  • Status: Recruiting
32.
33.
34.
35.
  • Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
  • This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 168 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment.
  • Diagnoses: Leukemia/MDS
  • Status: Recruiting
36.
37.
38.
Showing 31-38 of 38 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms